Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20 mg/m2 cisplatin on five days every four weeks an alternative to 100 mg/m2 cisplatin every three weeks?

Dirk Rades; Daniel Seidl; Stefan Janssen; Amira Bajrovic; Samer G. Hakim; Barbara Wollenberg; Katarina Karner; Primoz Strojan; Steven E. Schild

doi:10.1016/j.oraloncology.2016.06.004

Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20 mg/m2 cisplatin on five days every four weeks an alternative to 100 mg/m2 cisplatin every three weeks?

Dirk Rades^*, Daniel Seidl, Stefan Janssen, Amira Bajrovic, Samer G. Hakim, Barbara Wollenberg, Katarina Karner, Primoz Strojan, Steven E. Schild

^*Corresponding author for this work

7 Citations (Scopus)

Abstract

SummaryObjectives To compare chemoradiation with 100 mg/m² cisplatin every three weeks to 20 mg/m² on five days every four weeks for locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN). Materials and methods In 230 patients receiving chemoradiation for LASCCHN, 100 mg/m² cisplatin every three weeks (N = 126) and 20 mg/m² cisplatin on five days every four weeks (N = 104) were retrospectively compared. Chemoradiation plus eleven characteristics (T-/N-classification, performance score, gender, age, tumor site, grading, surgery, radiation technique, pre-chemoradiation hemoglobin, cumulative cisplatin dose) were analyzed for locoregional control (LRC), metastases-free survival (MFS) and overall survival (OS). Chemoradiation groups were compared for adverse events. Results On univariate analyses, chemoradiation had no impact on LRC (p = 0.53), MFS (p = 0.67) and OS (p = 0.14). On multivariate analysis of LRC, T-classification (p = 0.045) and hemoglobin (p < 0.001) were significant. On multivariate analysis of MFS, performance score (p = 0.028) was significant. On multivariate analysis of OS, performance score (p = 0.009) and hemoglobin levels (p = 0.002) achieved significance. Chemoradiation with 100 mg/m² cisplatin was associated with more pneumonia/sepsis (p = 0.003), grade ≥2 nausea/vomiting (p < 0.001), grade ≥2 nephrotoxicity (p = 0.005), grade ≥2 xerostomia (p = 0.002), grade ≥3 hematotoxicity (p = 0.052) and grade ≥2 ototoxicity (p = 0.048). Concluding statement 20 mg/m² cisplatin on five days every four weeks was associated with fewer adverse events than 100 mg/m² cisplatin every three weeks. 100 mg/m² cisplatin was not significantly superior to 20 mg/m² cisplatin regarding LRC, MFS and OS. Given the limitations of a retrospective study, 20 mg/m² cisplatin appeared preferable. The results should be confirmed in a randomized trial.

Original language	English
Journal	Oral Oncology
Volume	59
Pages (from-to)	67-72
Number of pages	6
ISSN	1368-8375
DOIs	https://doi.org/10.1016/j.oraloncology.2016.06.004
Publication status	Published - 01.08.2016

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.oraloncology.2016.06.004

Cite this

Rades, D., Seidl, D., Janssen, S., Bajrovic, A., Hakim, S. G., Wollenberg, B., Karner, K., Strojan, P., & Schild, S. E. (2016). Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20 mg/m2 cisplatin on five days every four weeks an alternative to 100 mg/m2 cisplatin every three weeks? Oral Oncology, 59, 67-72. https://doi.org/10.1016/j.oraloncology.2016.06.004

@article{a72f77f9a1a94ea2bc0323ab7f7963d6,

title = "Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20 mg/m2 cisplatin on five days every four weeks an alternative to 100 mg/m2 cisplatin every three weeks?",

abstract = "SummaryObjectives To compare chemoradiation with 100 mg/m2 cisplatin every three weeks to 20 mg/m2 on five days every four weeks for locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN). Materials and methods In 230 patients receiving chemoradiation for LASCCHN, 100 mg/m2 cisplatin every three weeks (N = 126) and 20 mg/m2 cisplatin on five days every four weeks (N = 104) were retrospectively compared. Chemoradiation plus eleven characteristics (T-/N-classification, performance score, gender, age, tumor site, grading, surgery, radiation technique, pre-chemoradiation hemoglobin, cumulative cisplatin dose) were analyzed for locoregional control (LRC), metastases-free survival (MFS) and overall survival (OS). Chemoradiation groups were compared for adverse events. Results On univariate analyses, chemoradiation had no impact on LRC (p = 0.53), MFS (p = 0.67) and OS (p = 0.14). On multivariate analysis of LRC, T-classification (p = 0.045) and hemoglobin (p < 0.001) were significant. On multivariate analysis of MFS, performance score (p = 0.028) was significant. On multivariate analysis of OS, performance score (p = 0.009) and hemoglobin levels (p = 0.002) achieved significance. Chemoradiation with 100 mg/m2 cisplatin was associated with more pneumonia/sepsis (p = 0.003), grade ≥2 nausea/vomiting (p < 0.001), grade ≥2 nephrotoxicity (p = 0.005), grade ≥2 xerostomia (p = 0.002), grade ≥3 hematotoxicity (p = 0.052) and grade ≥2 ototoxicity (p = 0.048). Concluding statement 20 mg/m2 cisplatin on five days every four weeks was associated with fewer adverse events than 100 mg/m2 cisplatin every three weeks. 100 mg/m2 cisplatin was not significantly superior to 20 mg/m2 cisplatin regarding LRC, MFS and OS. Given the limitations of a retrospective study, 20 mg/m2 cisplatin appeared preferable. The results should be confirmed in a randomized trial.",

author = "Dirk Rades and Daniel Seidl and Stefan Janssen and Amira Bajrovic and Hakim, {Samer G.} and Barbara Wollenberg and Katarina Karner and Primoz Strojan and Schild, {Steven E.}",

year = "2016",

month = aug,

day = "1",

doi = "10.1016/j.oraloncology.2016.06.004",

language = "English",

volume = "59",

pages = "67--72",

journal = "Oral Oncology",

issn = "1368-8375",

}